| Autor: |
Henze, G., Fengler, R., Hartmann, R., Dopfer, R., Göbel, U., Graf, N., Jürgens, H., Niethammer, D., Ritter, J., Schellong, G., Siegert, W. |
| Zdroj: |
Cancer Chemotherapy & Pharmacology; Jul1989, Vol. 24 Issue 1, pS16-S19, 4p |
| Abstrakt: |
Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant ( P<0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink